Ge healthcare pharmaco-economic study demonstrates adding breast oncology pet tracer to standard workup of patients with metastatic or recurrent breast cancer may yield beneficial clinical and economic outcomes, potentially saving $142m over five

Marlborough, mass.--(business wire)--  ge healthcare pharmaco-economic study demonstrates adding breast oncology pet tracer to standard workup of patients with metastatic or recurrent breast cancer may yield beneficial clinical and economic outcomes, potentially saving $142m over five years in the us in a ge healthcare sponsored pharmaco-economic study published in peer-reviewed journal plos one, the incidence, prevalence, diagnostic pathways, and treatments of different patients with metastati.
GEHC Ratings Summary
GEHC Quant Ranking